Enanta Pharmaceuticals (ENTA) Equity Ratio (2012 - 2026)

Enanta Pharmaceuticals has reported Equity Ratio for 15 years, with the latest figure at 0.37 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 27.92% year-over-year to 0.37; the trailing twelve-month figure through Mar 2026 stood at 0.37 (up 27.92% YoY), and the FY2025 full-year result was 0.23, down 32.59% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.37, down from 0.38 in the prior quarter.
• The five-year high for Equity Ratio was 0.88 in Q1 2022, with the low at 0.23 in Q3 2025.
• Historically, Equity Ratio has averaged 0.51 across 5 years, with a median of 0.4 in 2024.
• Annual changes were most pronounced in 2024 — Equity Ratio slumped 51.32% — and 2026, when it increased 27.92%.
• Enanta Pharmaceuticals' Equity Ratio stood at 0.87 in 2022, then slumped by 48.27% to 0.45 in 2023, then retreated by 28.38% to 0.32 in 2024, then advanced by 19.79% to 0.38 in 2025, then decreased by 3.57% to 0.37 in 2026.
• The last three Equity Ratio figures came in at 0.37 (Q1 2026), 0.38 (Q4 2025), and 0.23 (Q3 2025), per Business Quant data.